7 citations
,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
4 citations
,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.
June 2024 in “Journal of Clinical Oncology” EGFR-TKIs can cause unexpected skin, nail, and hair issues.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
1 citations
,
February 2021 in “Gastroenterology” A woman with inflammatory bowel disease improved after treatment with ustekinumab for a rare skin condition associated with her disease.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
July 2025 in “Journal of Dermatology Research and Therapy” Verteporfin may improve hair regrowth and reduce scarring after hair transplants.
3 citations
,
March 2025 in “Arthritis Research & Therapy” Combining fat grafts with botulinum toxin helps improve Raynaud's symptoms.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
September 2025 in “Journal of Dermatology Research and Therapy” Verteporfin with dermal wounding may boost hair regrowth in thinning areas but not in bald spots.
January 2019 in “Actas urológicas españolas” Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
90 citations
,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
January 2018 in “Journal of Crohn s and Colitis” High-dose intravenous iron therapy doesn't interfere with treatment improvements in IBD patients with iron deficiency anemia.
1 citations
,
January 2021 in “Research Square (Research Square)” Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
March 2023 in “JAAD case reports” Dutasteride and minoxidil helped regrow hair in a woman with breast cancer.
45 citations
,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
July 2018 in “DOAJ (DOAJ: Directory of Open Access Journals)” The new gel formula could improve the delivery of a hair loss treatment through the skin and might be an alternative to taking it by mouth.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
May 2024 in “Reactions weekly”
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.